Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral direct inhibitor of factor Xa, with those of enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty. METHODS: In this randomized, double-blind study, we assigned 4541 patients to receive either 10 mg of oral rivaroxaban once daily, beginning after surgery, or 40 mg of enoxaparin subcutaneously once daily, beginning the evening before surgery, plus a placebo tablet or injection. The primary efficacy outcome was the composite of deep-vein thrombosis (either symptomatic or detected by bilateral venography if the patient was asymptomatic), nonfatal pulmonary embolism, or death from any cause at 36 days (range, 30 to 42). The main secondary efficacy outcome was major venous thromboembolism (proximal deep-vein thrombosis, nonfatal pulmonary embolism, or death from venous thromboembolism). The primary safety outcome was major bleeding. RESULTS: A total of 3153 patients were included in the superiority analysis (after 1388 exclusions), and 4433 were included in the safety analysis (after 108 exclusions). The primary efficacy outcome occurred in 18 of 1595 patients (1.1%) in the rivaroxaban group and in 58 of 1558 patients (3.7%) in the enoxaparin group (absolute risk reduction, 2.6%; 95% confidence interval [CI], 1.5 to 3.7; P<0.001). Major venous thromboembolism occurred in 4 of 1686 patients (0.2%) in the rivaroxaban group and in 33 of 1678 patients (2.0%) in the enoxaparin group (absolute risk reduction, 1.7%; 95% CI, 1.0 to 2.5; P<0.001). Major bleeding occurred in 6 of 2209 patients (0.3%) in the rivaroxaban group and in 2 of 2224 patients (0.1%) in the enoxaparin group (P=0.18). CONCLUSIONS: A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once-daily, 40-mg subcutaneous dose of enoxaparin in patients undergoing elective total hip arthroplasty. The two drugs had similar safety profiles. (ClinicalTrials.gov number, NCT00329628.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We identified 1 RCT 317 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [317]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The investigation into the use of the lower doses of these 2 anticoagulants for secondary prevention was prompted by the desire to reduce the risk of bleeding, as well as the documented efficacy of the lower doses to prevent VTE after elective hip or knee arthroplasty. 317-321”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [317]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationThe Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., & Hylek, E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,528
Eriksson, B. I., Dahl, O. E., Rosencher, N., Kurth, A. A., van Dijk, C. N., Frostick, S. P., Prins, M. H., Hettiarachchi, R., Hantel, S., Schnee, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61445-7 · Cited by 1,116
Self-citationRoentgen Diagnosis of Venous Thrombosis in the Leg
Rabinov, K. (1972) · Archives of Surgery · doi:10.1001/archsurg.1972.04180020014004 · Cited by 740
Turpie, A. G. G. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.16.1833 · Cited by 736
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Kubitza, D., Becka, M., Wensing, G., Voith, B., & Zuehlsdorf, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0043-5 · Cited by 640
Eriksson, B. I., Bauer, K. A., Lassen, M. R., & Turpie, A. G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011100 · Cited by 631
Self-citationRosencher, N., Kerkkamp, H. E. M., Macheras, G., Munuera, L. M., Menichella, G., Barton, D. M., Cremers, S., Abraham, I. L., & Investigation, F. T. O. (2003) · Transfusion · doi:10.1046/j.1537-2995.2003.00348.x · Cited by 603
Eikelboom, J. W., Quinlan, D. J., & Douketis, J. D. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05249-1 · Cited by 513
Research works printed but not linked: 1
- 10.1016/s0140-6736(07)61445-7 · DOI · Paper page
Cited by
Items 501–600 of 1,000
Management of Bleeding Associated with Dabigatran and Rivaroxaban: A Survey of Current Practices
Kreuziger, L. B., & Reding, M. T. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.07.011 · Cited by 19
Inhibitors of propagation of coagulation: factors V and X
Toschi, V., & Lettino, M. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04001.x · Cited by 21
Kreutz, R. H., Haas, S. K., Holberg, G., Lassen, M. R., Mantovani, L. G., Schmidt, A., & Turpie, A. G. G. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12836 · Cited by 23
Self-citationLower limb immobilisation and venous thromboembolism risk: combined case–control studies
Braithwaite, I. E., Healy, B., Cameron, L., Weatherall, M., & Beasley, R. W. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2016-134365 · Cited by 22
Brockbank, J., & Wolowacz, S. E. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0486-4 · Cited by 20
Cardiac tachyarrhythmias and anaesthesia: General principles and focus on atrial fibrillation
Parida, S., & Thangaswamy, C. R. (2017) · Indian Journal of Anaesthesia · doi:10.4103/ija.ija_383_17 · Cited by 21
“[35-40] These drugs have also demonstrated a better safety profile and efficacy in comparison to low molecular weight heparin for the prevention of deep venous thrombosis, following major orthopaedic surgery.[40-44] However, perioperative management of patients on these newer non-Vitamin K antagonists may be challengi…”
BackgroundNon-hemorrhage-related adverse effects of rivaroxaban
Christopoulou, E. C., Filippatos, T. D., & Elisaf, M. (2017) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2017.72533 · Cited by 21
Huang, Q., Xing, S., Zeng, Y., Si, H., Zhou, Z., & Shen, B. (2019) · Orthopaedic Surgery · doi:10.1111/os.12542 · Cited by 23
Feng, W., Wang, X., Huang, D. F., & Lu, A. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105438 · Cited by 20
Chen, J., Lv, M., Wu, S., Jiang, S., Xu, W., Qian, J., Chen, M., Fang, Z., Zeng, Z., & Zhang, J. (2021) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2021.10.054 · Cited by 21
Liang, D., Lin, Q., Zhu, Q., Zhou, X., Fang, Y., Wang, L., Xiang, G., Zheng, K. I., Huang, W., & Shan, P. (2022) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.121.011555 · Cited by 19
Treatment of venous thromboembolism: guidelines translated for the clinician
Fekrazad, M. H., Lópes, R. D., Stashenko, G. J., Alexander, J. H., & Garcia, D. A. (2009) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-009-0374-7 · Cited by 19
“Based on high-quality evidence for safety and efficacy, dabigatran etexilate (an oral direct thrombin inhibitor) and rivaroxaban (an oral direct Xa inhibitor) are now available in Europe for primary prevention of VTE following major orthopedic surgery [32–35].”
BackgroundDirect oral anticoagulants: integration into clinical practice
Cowell, R. P. W. (2014) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2013-132474 · Cited by 23
Prodinger, P. M., Burgkart, R., Kreutzer, K., Liska, F., Pilge, H., Schmitt, A., Knoedler, M., Holzapfel, B. M., Hapfelmeier, A., Tischer, T., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159669 · Cited by 20
Boyd, R., DiCarlo, L. A., & Mandema, J. W. (2017) · Clinical and Translational Science · doi:10.1111/cts.12471 · Cited by 20
Wu, X., Xiao, P., Zhu, Z., Liu, J., Li, Y.-J., & Huang, W. C. (2019) · Medicine · doi:10.1097/md.0000000000015513 · Cited by 19
Lieberman, J. R. (2011) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/00124635-201112000-00001 · Cited by 19
Haykal, T., Kheiri, B., Zayed, Y., Barbarawi, M., Miran, M. S., Chahine, A., Katato, K., & Bachuwa, G. I. (2019) · Journal of Orthopaedics · doi:10.1016/j.jor.2019.02.032 · Cited by 19
RetractedAlshammari, T. M., Ata, S. I., Mahmoud, M. A., Alhawassi, T. M., & Aljadhey, H. S. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s161148 · Cited by 21
Murzina, E. L., Lobastov, K. V., Laberko, L. A., Dvornikov, A. S., & Popov, I. B. (2021) · Phlebology The Journal of Venous Disease · doi:10.1177/02683555211017336 · Cited by 18
Zhao, M., Bao, Y., Jiang, C., Chen, L., Xu, L., Liu, X., Li, J., Yang, Y., Jiang, G., Li, J. H., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.26945 · Cited by 19
Li, A., Zhang, M. C., Li, P., Eshaghpour, A., Li, K. T., Carrier, M., Wells, P. S., & Crowther, M. A. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.06.003 · Cited by 18
The discovery of rivaroxaban: translating preclinical assessments into clinical practice
Kubitza, D., Perzborn, E., & Berkowitz, S. D. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00145 · Cited by 20
“Analysis of data obtained across prespecified subgroups demonstrated consistent efficacy and safety outcomes irrespective of age or renal function (Eriksson et al., 2008; Kakkar et al., 2008; Lassen et al., 2008; Turpie et al., 2009; The EINSTEIN Investigators, 2010; Patel et al., 2011; Mega et…”
BackgroundMethodInfluentialMeredith, T., Schnegg, B., & Hayward, C. (2020) · Artificial Organs · doi:10.1111/aor.13848 · Cited by 18
Mandavia, R., Shalhoub, J., Head, K., & Davies, A. H. (2014) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2014.10.002 · Cited by 21
Turpie, A. G. G. (2012) · Therapeutic Advances in Hematology · doi:10.1177/2040620712453067 · Cited by 20
“[Eriksson et al. 2008; Kakkar et al. 2008; Lassen et al. 2008; Turpie et al. 2009].”
BackgroundMethodInfluentialBorris, L. C. (2009) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-009-0930-9 · Cited by 18
Self-citationMaratea, D., Fadda, V., Trippoli, S., & Messori, A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04421.x · Cited by 18
Prevention of VTE in orthopedic surgery patients
Spandonaro, F., Mancusi, R. L., Terranova, L., Giannarelli, D., Grossi, P., Imberti, D., & Mazza, E. L. (2013) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v14i2s.881 · Cited by 17
Dabigatran and rivaroxaban, new oral anticoagulants. New approaches in Dentistry
Moreno, G. G., Aguilar‐Salvatierra, A., Martín‐Piedra, M. Á., Guardia, J., Calvo‐Guirado, J. L., Cabrera, M. S., Lopez-Gallardo, C., & Castillo, T. (2010) · Journal of Clinical and Experimental Dentistry · doi:10.4317/jced.2.e1 · Cited by 20
Newer Oral Anticoagulant Agents: A New Era in Medicine
Goel, R., & Srivathsan, K. S. (2012) · Current Cardiology Reviews · doi:10.2174/157340312801784934 · Cited by 21
“The RECORD1 trial compared 10 mg of rivaroxaban daily (starting 6-8 hours postoperatively after THR) to 40 mg SQ of enoxaparin administered for 31-39 days [21].”
MethodPotential of new anticoagulants in patients with cancer
Weitz, J. I. (2010) · Thrombosis Research · doi:10.1016/s0049-3848(10)70009-8 · Cited by 20
The use of rivaroxaban for chemical thromboprophylaxis following total knee replacement
Rath, N. K., Goodson, M., White, S. P., & Forster, M. C. (2013) · The Knee · doi:10.1016/j.knee.2013.01.006 · Cited by 17
“The NICE thromboprophylaxis guidelines for lower limb arthroplasty was based on RECORD trials [9–12] which lacked endpoints to measure surgical outcomes like wound complication, infection, range of movement and chronic pain.”
MethodAnticoagulation therapy and proximal femoral fracture treatment
Ktistakis, I., Giannoudis, V. P., & Giannoudis, P. V. (2016) · EFORT Open Reviews · doi:10.1302/2058-5241.1.160034 · Cited by 17
Kanan, P. S., Schwartsmann, C. R., Boschin, L. C., CONRAD, S., & Silva, M. F. (2008) · Revista Brasileira de Ortopedia · doi:10.1590/s0102-36162008000800002 · Cited by 17
Antiplatelet and anticoagulation medications and the surgical patient
Yorkgitis, B. K., Ruggia-Check, C., & Dujon, J. (2013) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2013.04.004 · Cited by 19
“Rivaroxaban showed improved VTE prevention with a similar rate of major bleeding.(26,27) The oral administration of rivaroxaban results in predictable and dose-proportional anticoagulation without the need for dose adjustment or routine coagulation monitoring.”
BackgroundOgbonna, K. C., & Jeffery, S. M. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0075-y · Cited by 17
Martino, R. R. D., Beck, A. W., Edwards, M. S., Corriere, M. A., Wallaert, J. B., Stone, D. H., Cronenwett, J. L., & Goodney, P. P. (2012) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2012.02.066 · Cited by 17
Ruggieri, P., Montalti, M., Pala, E., Angelini, A., Calabrò, T., Errani, C., & Mercuri, M. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21645 · Cited by 17
“LMWH has been compared against Warfarin in several randomized clinical trials [1–22].”
BackgroundMethodResultInfluentialThe emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review
Pinto, D. J. P., Qiao, J. X., & Knabb, R. M. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.680438 · Cited by 17
Deep Vein Thrombosis in Orthopedic Surgery
Calfon, M. A., Seddighzadeh, A., Piazza, G., & Goldhaber, S. Z. (2009) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029608330471 · Cited by 17
Direct oral anticoagulants: a guide for daily practice
Fontana, P., Robert‐Ebadi, H., Bounameaux, H., Boehlen, F., & Righini, M. (2016) · Swiss Medical Weekly · doi:10.4414/smw.2016.14286 · Cited by 22
Anticoagulation for prosthetic heart valves
Yanagawa, B., Whitlock, R. P., Verma, S., & Gersh, B. J. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000259 · Cited by 17
Blin, P., Samama, C. M., Sautet, A., Bénichou, J., Lignot-Maleyran, S., Lamarque, S., Lorrain, S., Lassalle, R., Droz‐Perroteau, C., Mismetti, P., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.12.018 · Cited by 20
Perzia, B., Marquez, J., Mellia, J. A., Jou, C., Othman, S., Basta, M. N., Fischer, J. P., Labropoulos, N., & Khan, S. U. (2021) · Aesthetic Surgery Journal · doi:10.1093/asj/sjab090 · Cited by 17
Barriers to the optimal use of anticoagulants after orthopaedic surgery
Borris, L. C. (2008) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-008-0765-9 · Cited by 18
“thromboprophylaxis following elective THA or TKA, with a comparable safety proWle [18, 26, 28].”
BackgroundSelf-citationRivaroxaban for the Treatment of Pulmonary Embolism
Vanassche, T., & Verhamme, P. B. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0041-4 · Cited by 18
“for thromboprophylaxis after knee and hip replacement surgery, without a clinically significant excess of bleeding events [17–20].”
BackgroundFacts and artefacts of coagulation assays for factor Xa inhibitors
Haas, S. K. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-01-0080 · Cited by 17
Self-citationHe, Q., Wei, Y., Qian, Y., & Zhong, M. (2024) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2024.02.003 · Cited by 17
Direct Oral Anticoagulants: Quick Primer on When to Use and When to Avoid
Bejjani, A., & Bikdeli, B. (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2451-4014 · Cited by 18
Thromboprophylaxie périopératoire : brève revue et recommandations
Samama, C. M. (2008) · Annales Françaises d Anesthésie et de Réanimation · doi:10.1016/s0750-7658(08)75140-2 · Cited by 18
The Role of Apixaban for Venous and Arterial Thromboembolic Disease
Prom, R., & Spinler, S. A. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q119 · Cited by 21
Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial
Paikin, J. S., Manolakos, J. J., & Eikelboom, J. W. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.91 · Cited by 19
Use of New Oral Anticoagulants in the Treatment of Venous Thromboembolism and Thrombotic Prophylaxis
Akin, M., Schäfer, A., Akın, İ., Widder, J. D., & Brehm, M. U. (2015) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x1502151209110620 · Cited by 19
Yan, X., Gu, X., Xu, Z., Lin, H., & Wu, B. Y. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0460-0 · Cited by 16
“Hazard ratio of rivaroxaban versus enoxaparin [18, 19]”
MethodRahmanzade, R., Cabrera-Diaz, F., Zaugg, C., Schüetz, P., & Salili, A. R. (2020) · Thrombosis Journal · doi:10.1186/s12959-020-00227-w · Cited by 17
Torres, C. M., & Haut, E. R. (2020) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000771 · Cited by 18
Jang, S., Shin, W. C., Song, M. K., Han, H., Lee, M. C., & Ro, D. H. (2021) · Knee Surgery and Related Research · doi:10.1186/s43019-021-00093-4 · Cited by 16
Winchester, C. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s26482 · Cited by 17
Spencer, R. J., & Amerena, J. V. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0127-2 · Cited by 16
“Studies have demonstrated efficacy at preventing venous thromboembolism (VTE) after major, elective orthopedic surgery [16], in the treatment of acute VTE [17, 18], and in stroke prevention in patients with AF [19].”
BackgroundDuran, A. A., Sengupta, N., Diamantopoulos, A., Forster, F., Kwong, L. M., & Lees, M. (2011) · Journal of Medical Economics · doi:10.3111/13696998.2011.623203 · Cited by 16
“(5) All patients developing a PE would be treated on an inpatient basis.”
BackgroundTiming the First Postoperative Dose of Anticoagulants
Paikin, J. S., Hirsh, J., Chan, N., Ginsberg, J. S., Weitz, J. I., & Eikelboom, J. W. (2015) · CHEST Journal · doi:10.1378/chest.14-2710 · Cited by 16
Laurent, M., Joimel, U., Varin, R., Cazin, L., Gest, C., Lecam-Duchez, V., Jin, J., Liu, J., Vannier, J., Lu, H., et al. (2014) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-3-30 · Cited by 18
“The higher efficiency of rivaroxaban demonstrated in our study is interesting because clinical studies also reported the reduction of thrombotic events in the rivaroxaban treated patients group for hip and knee replacement in comparison to the enoxaparin-treated groups [38-41].”
Limit the Bleeding, Limit the Pain in Total Hip and Knee Arthroplasty
Friedman, R. J. (2010) · Orthopedics · doi:10.3928/01477447-20100722-62 · Cited by 16
Self-citationHow we treat bleeding associated with direct oral anticoagulants.
Marano, G., Vaglio, S., Pupella, S., Liumbruno, G. M., & Franchini, M. (2016) · Europe PMC (PubMed Central) · doi:10.2450/2016.0180-15 · Cited by 18
The role of new oral anticoagulants in orthopaedics: an update of recent evidence
Papadopoulos, D. V., Kostas‐Agnantis, I., Gkiatas, I. S., Tsantes, A. G., Ziara, P., & Korompilias, A. V. (2017) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.1007/s00590-017-1940-x · Cited by 16
Tyagi, V., Tomaszewski, P. M., Lukasiewicz, A. M., Theriault, S., & Pelker, R. R. (2017) · Orthopedics · doi:10.3928/01477447-20171114-06 · Cited by 16
Udayachalerm, S., Rattanasiri, S., Angkananard, T., Attia, J. R., Sansanayudh, N., & Thakkinstian, A. (2018) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029618796339 · Cited by 16
Kwok, C. S., Pradhan, S., Yeong, J. K.-Y., & Loke, Y. K. (2013) · CHEST Journal · doi:10.1378/chest.12-2634 · Cited by 17
Gunn, S., Sonesson, E., Peerlinck, K., Vanassche, T., Vandenbriele, C., Ageno, W., Glazer, S., Prins, M. H., Buller, H. R., Tangelder, M. J. D., et al. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-01-0066 · Cited by 17
“Rivaroxaban, the comparative treatment in the current trial, was more effective for the prevention of VTE after THR over five weeks than enoxaparin 40 mg (8).”
BackgroundMethodKarampinas, P. K., Megaloikonomos, P. D., Lampropoulou-Adamidou, K. I., Papadelis, E. G., Mavrogenis, A. F., Vlamis, J., & Pneumaticos, S. G. (2018) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.1007/s00590-018-2307-7 · Cited by 16
Should deep venous thrombosis prophylaxis be used in fast-track hip and knee replacement?
Kjærsgaard‐Andersen, P., & Kehlet, H. (2012) · Acta Orthopaedica · doi:10.3109/17453674.2012.672094 · Cited by 18
New Anticoagulants — The Path from Discovery to Clinical Practice
Lohrmann, J., & Becker, R. C. (2008) · New England Journal of Medicine · doi:10.1056/nejme0804291 · Cited by 18
Novel Anticoagulants for Atrial Fibrillation: A Critical Appraisal
Tzeis, S. E., & Andrikopoulos, G. K. (2011) · Angiology · doi:10.1177/0003319711422808 · Cited by 17
Ding, K., Yan, W., Zhang, Y., Li, J., Li, C., & Liang, C. (2024) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2024.02.113 · Cited by 18
Cheok, T. S., Beveridge, A., Berman, M., Coia, M., Campbell, A., Tse, T. T. S., Doornberg, J. N., & Jaarsma, R. L. (2024) · The Bone & Joint Journal · doi:10.1302/0301-620x.106b9.bjj-2023-1252.r2 · Cited by 15
Guasti, L., Fumagalli, S., Afilalo, J., Geisler, T., Abreu, A., Ambrosetti, M., Gevaert, S., Christodorescu, R., Richter, D. J., Aboyans, V., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf010 · Cited by 17
Novel Oral Anticoagulants for VTE Prevention in Orthopedic Surgery: Overview of Phase 3 Trials
Friedman, R. J. (2011) · Orthopedics · doi:10.3928/01477447-20110826-24 · Cited by 16
Self-citationReview: Will Warfarin Ever Be Replaced?
Ruff, C. T., & Braunwald, E. (2010) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248410366448 · Cited by 18
“0001), in patients undergoing total hip arthroplasty.(34,35) RECORD 3 demonstrated a 49% relative risk reduction (P < .”
BackgroundYang, W., Fan, S., Guo, Q., Hao, J., Li, H., Yang, S., Zhao, W., Zhang, J., & Hu, Y. (2016) · The Journal of Chemical Thermodynamics · doi:10.1016/j.jct.2016.01.022 · Cited by 15
Green, B., Mendes, R. A., der Valk, R. V., & Brennan, P. A. (2016) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12441 · Cited by 17
Bala, A., Murasko, M. J., Burk, D. R., Huddleston, J. I., Goodman, S. B., Maloney, W. J., & Amanatullah, D. F. (2019) · Hip International · doi:10.1177/1120700019841600 · Cited by 17
Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis
Tun, H. N., Kyaw, M. T., Rafflenbeul, E., & Suástegui, X. L. (2022) · European Cardiology Review · doi:10.15420/ecr.2021.55 · Cited by 21
Parry, T. J., Huang, Z., Chen, C., Connelly, M. A., Perzborn, E., Andrade‐Gordon, P., & Damiano, B. P. (2011) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e32834cb30e · Cited by 16
Efficacy and safety of novel anticoagulants compared with established agents
Rybak, I., Ehle, M., Buckley, L. F., & Fanikos, J. R. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711408489 · Cited by 15
“Venous thromboembolism prophylaxis RECORD 1 and RECORD 2 evaluated rivaroxaban for VTE prophylaxis in total hip replacement surgery, while RECORD 3 and RECORD 4 enrolled patients requiring total knee replacement surgery [Turpie et al. 2009b; Eriksson et al. 2008; Kakkar et al. 2008; Lassen et al. 2008] (Table 3).”
BackgroundMethodInfluentialSamama, C. M., & Godiér, A. (2011) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e328343cd4b · Cited by 16
Rivaroxaban: An Oral Direct Factor Xa Inhibitor for the Prevention of Thromboembolism
Chen, T., & Lam, S. (2009) · Cardiology in Review · doi:10.1097/crd.0b013e3181aa2154 · Cited by 16
Gombár, C., Horváth, G., Gálity, H., Sisák, K., & Tóth, K. (2014) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-014-1933-8 · Cited by 15
Berkovits, A., Aizman, A., Zúñiga, P., Pereira, J. I., & Mezzano, D. (2011) · Revista médica de Chile · doi:10.4067/s0034-98872011001000016 · Cited by 21
Shantsila, E., & Lip, G. Y. H. (2010) · doi:10.1007/978-1-908517-08-1_5 · Cited by 15
Ageno, W. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.37 · Cited by 16
Bilateral adrenal gland hemorrhage in a patient treated with rivaroxaban
Comuth, W., Christiansen, J. J., Münster, A. B., & Husted, S. (2016) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000541 · Cited by 15
Management of rivaroxaban in relation to bodyweight and body mass index
Uprichard, J. (2016) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716643645 · Cited by 16
“Each of the RECORD studies demonstrated superiority of rivaroxaban over enoxaparin for reductions in the primary efficacy endpoint (the composite of symptomatic and asymptomatic DVT, nonfatal PE, and all-cause mortality) and a similar profile for the main safety outcome (major bleeding) [Eriksson et al. 2008; Kakkar e…”
MethodResultReview of Direct Oral Anticoagulants and Guide for Effective Drug Utilization
Khachatryan, T., Hauschild, C., Hoff, J., Contractor, T. A., Khachatryan, A., Tran, H. N., Matsuo, B., Jacobson, A. K., & Hilliard, A. A. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00344-6 · Cited by 15
Shansky, Y. D., Sergeeva, N. S., Sviridova, I. K., Karalkin, P. A., Kirsanova, V. A., Akhmedova, S. A., Фомичева, К. А., Shkurnikov, M. Y., Портянникова, А. Ю., & Каприн, А. Д. (2019) · Cells Tissues Organs · doi:10.1159/000502813 · Cited by 15
The Pharmacology, Efficacy, and Safety of Rivaroxaban in Obese Patient Populations
Ashton, V., Mudarris, L., & Moore, K. T. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00434-w · Cited by 15
Wood, R. C., Stewart, D. W., Slusher, L., El‐Bazouni, H., Cluck, D. B., Freshour, J. E., & Odle, B. L. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1608 · Cited by 15
Peidro-Garcés, L., Otero-Fernández, R., & Lozano-Lizarraga, L. (2013) · Revista Española de Cirugía Ortopédica y Traumatología · doi:10.1016/j.recote.2013.01.005 · Cited by 17
VTE primary prevention, including hospitalised medical and orthopaedic surgical patients
Granziera, S., & Cohen, A. T. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-10-0823 · Cited by 20
“Extended duration thromboprophylaxis regimens have successfully reduced the incidence of VTE in postoperative patients (29); however, acute medically ill patients have not been shown to obtain a favourable benefit-to-risk ratio from longer periods of prophylaxis with LMWH or NOACs (30, 31).”
BackgroundTreatment options in heparin-induced thrombocytopenia
Hook, K. M., & Abrams, C. S. (2010) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32833c07a7 · Cited by 16
Metadata
- Authors
- Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., & Geerts, W.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Aarhus University Hospital (DK)
- Medical University of South Carolina (US)
- Technical University of Munich (DE)
- Leiden University Medical Center (NL)
- Queen Mary University of London (GB)
- Bayer (Germany) (DE)
- University of Toronto (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-06-26
- Volume
- 358
- Issue
- 26
- Pages
- 2765-2775
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2014491911
- Cited by
- 1,433
- References
- 25
- Citations by year
- 2026: 15 · 2025: 28 · 2024: 24 · 2023: 35 · 2022: 39 · 2021: 55 · 2020: 47 · 2019: 47 · 2018: 60 · 2017: 68 · 2016: 86 · 2015: 92 · 2014: 98 · 2013: 167 · 2012: 159
- FWCI
- 76.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IrInSubria (University of Insubria) (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- rivaroxaban, enoxaparin, thromboprophylaxis, total hip arthroplasty, venous thromboembolism, deep vein thrombosis, pulmonary embolism, factor Xa inhibitors, major bleeding, postoperative anticoagulation
- MeSH terms
- Rivaroxaban, Adolescent, Adult, Aged, Aged, 80 and over, Anticoagulants, Double-Blind Method, Female, Humans, Male, Middle Aged, Morpholines, Pulmonary Embolism, Thiophenes, Enoxaparin, Arthroplasty, Replacement, Hip, Venous Thrombosis, Venous Thromboembolism, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.